Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Express Scripts
Fish and Richardson
Moodys
Boehringer Ingelheim
Mallinckrodt
QuintilesIMS
Julphar
Merck
Harvard Business School

Generated: January 18, 2018

DrugPatentWatch Database Preview

Cefixime - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cefixime and what is the scope of cefixime freedom to operate?

Cefixime
is the generic ingredient in two branded drugs marketed by Lupin Ltd, Aurobindo Pharma Ltd, Belcher Pharms Llc, Lederle, and Lupin Pharms, and is included in eleven NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Cefixime has two patent family members in two countries.

There are fourteen drug master file entries for cefixime. Eight suppliers are listed for this compound.
Pharmacology for cefixime
Medical Subject Heading (MeSH) Categories for cefixime

US Patents and Regulatory Information for cefixime

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-003 Oct 25, 2010 RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lederle SUPRAX cefixime TABLET;ORAL 050621-001 Apr 28, 1989 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma Ltd CEFIXIME cefixime FOR SUSPENSION;ORAL 204835-002 Apr 14, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Belcher Pharms Llc CEFIXIME cefixime FOR SUSPENSION;ORAL 206938-001 Feb 6, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lupin Ltd SUPRAX cefixime CAPSULE;ORAL 203195-001 Jun 1, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lederle SUPRAX cefixime TABLET;ORAL 050621-002 Apr 28, 1989 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lupin Ltd SUPRAX cefixime FOR SUSPENSION;ORAL 202091-001 Feb 20, 2013 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lupin Pharms SUPRAX cefixime FOR SUSPENSION;ORAL 065129-001 Feb 23, 2004 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-001 Oct 25, 2010 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-002 Oct 25, 2010 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for cefixime

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905 Pharmaceutical compositions of Cefixime ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
QuintilesIMS
Queensland Health
Accenture
Mallinckrodt
US Department of Justice
Federal Trade Commission
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot